Sign In
Buy KOD
$33.87
+0.655 (+1.97%)
At Close: Jun 03, 2026
Kodiak Sciences (KOD) Focuses on Developing Eye Drug Tarcocimab
01:33pm, Friday, 19'th Aug 2022
Kodiak Sciences (KOD) lead pipeline candidate, tarcocimab, being developed for treating various retinal vascular diseases, holds potential. Stiff competition in the market remains a woe.
Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus
12:02pm, Wednesday, 10'th Aug 2022
Kodiak Sciences (KOD) reports narrower-than-expected loss for the second quarter of 2022. The focus is on the lead candidate, KSI-301, which is being developed for treating various retinal vascular di
Kodiak Sciences: All Eyes For A Sentiment Turnaround After Positive Beacon Results
01:58pm, Monday, 08'th Aug 2022
Kodiak Sciences is a biotech company looking to improve standard of care in different eye indications. In February 2022, the stock had sold off 80% on a Phase 2b/3 failure, and never recovered.
Why Kodiak Sciences Stock Is Sharply Lower Today
12:07pm, Tuesday, 02'nd Aug 2022
An analyst downgrade is weighing on the drugmaker's stock price today.
Why Is Kodiak Sciences Inc. (KOD) Up 88.3% Since Last Earnings Report?
12:47pm, Thursday, 09'th Jun 2022
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak Sciences to Present at the Jefferies Global Healthcare Conference
08:00am, Friday, 27'th May 2022
PALO ALTO, Calif. , May 27, 2022 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prev
Kodiak Sciences: Potential For Comeback After Trial Setback
09:09am, Tuesday, 17'th May 2022
Results from the BEACON study, which is using KSI-301 for the treatment of patients with retinal vein occlusion, are expected by Q3 of 2022. The global retinal vein occlusion market is estimated to be
Kodiak Sciences (KOD) Q1 Loss Widens, Eye Candidate in Focus
02:18pm, Wednesday, 11'th May 2022
Kodiak Sciences (KOD) reports wider-than-expected loss in the first quarter of 2022. Focus is on lead candidate, KSI-301, being developed for treating various retinal vascular diseases.
Should You Buy Kodiak (KOD) Ahead of Earnings?
10:32am, Friday, 06'th May 2022
Kodiak (KOD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bonds Are Screaming “Recession.” That's Great News For One Top Sector.
04:44pm, Tuesday, 29'th Mar 2022
The 10-2 year treasury yield spread is close to zero. Here's what you should do about this warning sign of a coming recession.
2 Net Current Asset Value Stocks to Consider
05:32pm, Wednesday, 23'rd Mar 2022
There are some investors who buy U.S.-listed stocks that are trading below their liquidation value because they believe there is a lot to gain in these stocks after the market reprices shares to near
2 Dirt Cheap Biotechs to Buy If You're a Contrarian
11:07am, Saturday, 05'th Mar 2022
Today's losers are selling for peanuts, and they just might become tomorrow's winners.
Kodiak Sciences (KOD) Q4 Loss Widens, Eye Candidate in Focus
11:29am, Wednesday, 02'nd Mar 2022
Kodiak Sciences (KOD) reports a wider-than-expected loss for the fourth quarter of 2021. It is focusing on the lead candidate, KSI-301, being developed for treating various retinal vascular diseases.
Why Kodiak Sciences (KOD) Might Surprise This Earnings Season
09:57am, Wednesday, 02'nd Mar 2022
Kodiak Sciences (KOD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Here's Why Kodiak Sciences Inc. (KOD) is Poised for a Turnaround After Losing 82.3% in 4 Weeks
11:30am, Friday, 25'th Feb 2022
Kodiak Sciences Inc. (KOD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings
